Ulipristal Tablet | ULIPSTALL 5

Description

Ulipristal Tablet ULIPSTALL 5 contains Ulipristal acetate 5 mg, a selective progesterone receptor modulator (SPRM) used in the management of uterine fibroids (leiomyomas) in women of reproductive age. Ulipristal works by binding to progesterone receptors, thereby reducing the effects of progesterone on the uterus. This action helps in reducing the size of fibroids, controlling heavy menstrual bleeding, and improving overall quality of life. Unlike surgical interventions, ULIPSTALL 5 provides a non-invasive, oral treatment option for women suffering from fibroid-related symptoms. It is generally prescribed for short-term use in treatment cycles under strict medical supervision. Uses of ULIPSTALL 5 ULIPSTALL 5 is mainly prescribed for: Management of Uterine Fibroids (Leiomyomas): Helps reduce fibroid size. Controls heavy and prolonged menstrual bleeding. Improves anemia caused by excessive blood loss. Preoperative Treatment Before Fibroid Surgery: Shrinks fibroid size, making surgery less complicated. Reduces bleeding, improving surgical outcomes. Improvement in Quality of Life: Decreases pelvic pain and pressure symptoms caused by fibroids. Restores normal menstrual cycles after treatment cycles. Side Effects of ULIPSTALL 5 Like all medicines, ULIPSTALL 5 may cause some side effects. Most are mild and temporary, but some require medical attention. Common Side Effects: Headache Abdominal pain or discomfort Nausea Fatigue Breast tenderness Hot flushes Less Common but Serious Side Effects: Liver function abnormalities (in rare cases, serious liver injury) Endometrial changes (thickening of the uterine lining, usually reversible after treatment) Allergic reactions such as rash, itching, or swelling It is important to undergo regular monitoring, especially of liver function, during treatment. Precautions Before Using ULIPSTALL 5 Do not take ULIPSTALL 5 if you are allergic to Ulipristal acetate. Not recommended in women with liver disease, unexplained vaginal bleeding, or hormone-dependent cancers. Not suitable for use during pregnancy or breastfeeding. Regular liver function tests should be done before and during treatment. Long-term continuous use is not recommended; treatment is given in cycles under a doctor’s supervision. Inform your doctor if you have a history of endometrial disorders or abnormal bleeding patterns. Drug Interactions of ULIPSTALL 5 CYP3A4 inhibitors (like ketoconazole, itraconazole, clarithromycin): Increase ulipristal levels in the body, leading to higher risk of side effects. CYP3A4 inducers (like rifampicin, carbamazepine, phenytoin, St. John’s Wort): Decrease the effectiveness of the drug. Hormonal contraceptives: May reduce the effectiveness of either medicine; alternative contraceptive methods are recommended during treatment. Grapefruit juice: Can affect the metabolism of ulipristal and should be avoided. Conclusion ULIPSTALL 5 (Ulipristal 5 mg Tablets) is a highly effective oral therapy for women suffering from symptomatic uterine fibroids. By reducing fibroid size, controlling heavy menstrual bleeding, and improving anemia, it offers a non-surgical solution for many women. Its role as a preoperative treatment further adds value by improving surgical outcomes when surgery is needed. While ULIPSTALL 5 is generally well tolerated, it requires careful medical supervision, liver monitoring, and proper treatment cycles to ensure safety and effectiveness. For women looking for an alternative to surgery, ULIPSTALL 5 provides hope for symptom relief, better menstrual control, and enhanced quality of life.